Pharmaceuticals Witness 10.4% Increase in Therapy Initiation for Top 10 Rare Diseases

Pharmaceuticals Witness 10.4% Increase in Therapy Initiation for Top 10 Rare Diseases

A recent case study by AllazoHealth reports that a leading pharmaceutical company specializing in rare diseases achieved a notable 10.4% increase in therapy initiation through the implementation of AI-enhanced patient outreach and customized, multi-channel communications.

This research underscores how AllazoHealth’s AI-driven personalization approach enabled the pharmaceutical company to effectively time and adapt its messages for patients, caregivers, infusion centers, and healthcare providers across various therapy options, including complex administration methods such as clinic and home infusions, self-injections, and oral therapies. The strategic targeting led to not only increased therapy initiation but also improved adherence rates, with therapy discontinuation reduced by 7.3%, illustrating the transformative role of AI in patient support.

Before collaborating with AllazoHealth, the company relied heavily on nurse-led outreach efforts. While these high-touch methods were effective, they demanded significant resources and posed challenges in scalability, particularly for patients dealing with rare diseases characterized by unique complexities and specialized requirements.

The introduction of AllazoHealth’s AI-powered system brought a scalable alternative that allowed for the customization of messages according to each patient’s circumstances. This included aspects such as timing and frequency, message content, and the choice of communication channels like SMS, email, and live calls. The AI solution helped guide patients through essential therapy journey stages while simultaneously reducing operational expenses and enhancing patient outcomes.

The implications of AllazoHealth’s AI solution were extensive, impacting around 10,000 patients and extending to caregivers and healthcare professionals. The AI system provided daily personalized updates, prioritizing communication attempts based on numerous factors such as past interactions, expected responses, and optimal contact times. This approach fostered a proactive model of support that improved patient onboarding experiences, sustained treatment engagement, and minimized the outreach calls required from nursing staff. Nurses expressed heightened job satisfaction, feeling they could make a more meaningful impact on patients’ lives due to the improved efficiency and communication streamlining.

William Grambley, CEO of AllazoHealth, highlighted the significance of these findings, stating that the outcomes not only surpassed the initial goals but also showcased AI’s potential to create measurable advancements in health outcomes.

He noted: “The outcomes of this case study exceeded our expectations, allowing us to reduce non-clinical discontinuation rates while boosting therapy starts. AllazoHealth was able to anticipate individual patient behaviors and tailor each communication with appropriate content and timing, resulting in a next-best-action model that delivers improved outcomes and reduced costs.”

This technology provided a strategic edge for the pharmaceutical company in a competitive environment, illustrating how AI can effectively lower therapy discontinuation rates in areas of significant patient need. In the challenging landscape of healthcare, where adherence to therapy is critical, AllazoHealth’s data-driven, proactive strategy emerges as a viable solution that balances cost-effectiveness and operational efficiency with outstanding patient support. With a focus on HIPAA compliance and utilizing Microsoft Azure, AllazoHealth’s platform is structured to enhance biopharma outreach, adapting to evolving patient needs while ensuring security and scalability.

In a landscape where precision in patient support and adherence is crucial, AllazoHealth asserts that its targeted methodology is vital for biopharma companies navigating complex patient journeys and financial constraints. With a HIPAA-compliant, HITRUST-certified platform, AllazoHealth continues to lead the way in AI-driven solutions across therapeutic areas, amplifying engagement through the secure and scalable infrastructure provided by Microsoft Azure.